Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth.

What Was Tested

This controlled clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Baseline investigations were then performed using dual-energy x-ray absorptiometry (body composition), lipid measurements, and assessment of insulin sensitivity by both homeostasis model assessment and a short insulin tolerance test.

No endocrine differences were evident between the groups at baseline.

Who Took Part

The study group was 24 adolescents.

The age groups tagged for this paper are teenagers and adults, both men and women.

How the Study Was Run

The design is described as parallel-group.

Groups ran in parallel: each of the adolescents stayed in one arm throughout.

The groups were followed up in parallel with repeat observations made after 6 and 12 months.

What Was Measured

Baseline investigations were then performed using dual-energy x-ray absorptiometry (body composition), lipid measurements, and assessment of insulin sensitivity by both homeostasis model assessment and a short insulin tolerance test.

The subject headings attached to it are Body Composition, Growth Hormone, Human Growth Hormone, Insulin Resistance, Insulin-Like Growth Factor I, Lipids and Metabolism, Inborn Errors.

What This Means in Plain Language

The paper is a parallel-group study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 24 adolescents.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2004 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.